A Study to Track How the Healthy Male Participants Handles the New Oral Drug RO7795081 for Weight Management and Diabetes

2025-524210-28-00 Protocol BP45932 Human pharmacology (Phase I) - Other Ended

Start 17 Feb 2026 · End 17 Apr 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol BP45932

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 10
Countries 1
Sites 1

Not Applicable

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Health Care [N] - Population Characteristics [N01]
Trial duration
17 Feb 2026 → 17 Apr 2026
Decision date (initial)
2026-02-11
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Not Applicable

VersionLevelCodeTermSystem organ class
20.0 PT 10029883 Obesity 100000004861
24.1 PT 10033307 Overweight 100000004861

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 10 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2026-02-17 2026-04-17 2026-02-23 2026-03-11

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-12-11 Netherlands Acceptable
2026-02-09
2026-02-11
2 SUBSTANTIAL MODIFICATION SM-1 2026-03-12 Netherlands Acceptable
2026-03-24
2026-03-24